ClinicalTrials.gg
CompletedNCT03745742HRV REEDUCUpdated Nov 26, 2018

Post Myocardial Infarction's Rehabilitation Guided by Heart Rate Variability

An interventional study of HRV measurement in Myocardial Infarction and Cardiac Rehabilitation, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-26.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Mar 2016, registered Nov 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Cardiac rehabilitation reduces morbidity and mortality after myocardial infarction (MI) and improve the sympathovagal balance. The autonomic nervous system (ANS) can be explored by the variation of heart rate (HRV). The HRV is a fatigue marker and guides the athletes training programs. A smartphone app can measure the HRV via a heart rate monitor.

The main study objective is to compare the effect on the functional capacities of a re-training adapted to the HRV compared to a standard program in the post-MI The secondary objective is to compare the patients' quality of life according to the rehabilitation program and to validate the HRV smartphone app.

This is a prospective, multicenter study. Post-MI patients treated with angioplasty with a LVEF> 40% are randomized into 2 groups: HRV (re-training adapted to HRV daily: 10W decrease or increase in workload according to the HRV) or control (continuous training in SV1). Patients underwent a cardiopulmonary test, a walking test (TM6) and a SF36 questionaries' at the entrance and exit. The taking of HRV was done every morning in a standardized way via the smartphone app during the 20 re-training sessions.

Read the detailed description

Description of the study:

Patients with myocardial infarction (STEMI or NSTEMI) without alteration of left ventricle systolic function, agreeing to participate at a cardiac rehabilitation program will be included in the study and randomized into two groups:

  • Group A (= control): standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.)
  • Group B (= strategy to the study): individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).

The duration of the rehabilitation program will be 4 weeks with 5 training sessions per week (Monday to Friday), or 20 training sessions. At the end of the program, patients will benefit from an assessment of functional abilities and their quality of life.

02

Conditions studied

  • Myocardial Infarction
  • Cardiac Rehabilitation

Keywords

  • Cardiac rehabilitation
  • myocardial infarction
  • heart rate variability
  • physical fitness
03

In context

Myocardial Infarction

2,779 studies on the registry are indexed under Myocardial Infarction; 417 are open to participants now.

This study's enrollment of 80 is below the median of 148 across 1,613 interventional studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 854 studies on the registry; 180 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man, Woman ≥18 years old and \<70 years old
  • STEMI or NSTEMI having undergone angioplasty revascularization at least 8 day before the beginning of reeducation
  • Sinus rhythm
  • LVEF> 40% (Simpson Biplane echocardiography

Exclusion criteria

Exclusion Criteria:

  • Contraindications to cardiac re-training:
  • Ventricular or supraventricular rhythm disorder
  • Heart failure.
  • Pericardial effusion.
  • STEMI or NSTEMI \<J8
  • NSTEMI or STEMI , post revascularization by bypass surgery
  • Non-sinus rhythm
  • Comorbidity preventing all sports activity: severe AOMI; amputation; neurological disorder, hemiplegia.
  • Pathology leading to modifications of the HRV:
  • Chronic lung disease
  • Renal insufficiency with clearance \<30 ml / min (MDRD)
  • LVEF \<40%
  • Electrical cardiac stimulation
  • Linked to the person:
  • Protected Majors
  • People unable to express their consent.
  • Pregnant woman
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Other
    control

    standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.

    Other: HRV measurement

  • Experimental
    study strategy

    individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).

    Other: HRV measurement

Interventions

  • OtherHRV measurement

    Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max). * Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days. HRV is measured every day in each group via a heart rate belt and a smartphone App.

    Also known as: Rehabilitation program based on HRV measurement

06

What researchers measure

Primary outcomes

  1. gain of VO2max

    The gain obtained after 4 weeks of cardiac rehabilitation(expressed as% basal value) of VO2max

    Time frame: after 4 weeks of cardiac rehabilitation

Secondary outcomes

  1. patients'quality of life after 4 weeks of cardiac rehabilitation

    The taking of HRV was done every morning in a standardized way via the smartphone app during the 20 re-training sessions.

    Time frame: after 4 weeks of cardiac rehabilitation

  2. The patient's functional capacity after 4 weeks of cardiac rehabilitation estimated by the distance covered during the 6-minute walk test.

    The gain in meter at the 6 minutes' walk test

    Time frame: after 4 weeks of cardiac rehabilitation

07

Study locations

1 site
  • Chu Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2017, 17 months.

Of 402 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 17 months is below that.

Counting every sponsor, half of 438 studies reached it within 32 months; a quarter within 15 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Nov 19, 2018
StartActual
Mar 1, 2016
Primary completionActual
Aug 31, 2017
CompletionActual
Sep 30, 2017
Last update
Nov 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03745742
Collaborators
Clinical Of Medical Cardio Pneumologie, Durtol, Almerys
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Mar 1, 2016
Primary completion
Aug 31, 2017
Completion
Sep 30, 2017
Last update
Nov 26, 2018

Study contacts

D'Agrosa Boiteux Marie-Claire
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion